Broadfin Capital, LLC historic quarter change: USA Stocks, Added
In share positions in stocks (listed in the US), over 13 quarters from 2013-06-30 to 2016-09-30, Broadfin Capital, LLC opened 26 positions, added to 33, reduced 48 and sold out of 30.
- Q3 2016: Stock HRTX; Country of operation United States; Class COM; Shares before 1,250,104.
- Q3 2016: Stock DVAX; Country of operation United States; Class COM NEW; Shares before 547,810.
- Q3 2016: Stock PCRX; Country of operation United States; Class COM; Shares before 93,380.
- Q2 2016: Stock ANGO; Country of operation United States; Class COM; Shares before 2,498,527.
Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1511901), 13 quarters: Q3 2016 (2016-06-30 to 2016-09-30, filed 2016-11-14); Q2 2016 (2016-03-31 to 2016-06-30, filed 2016-08-15); Q1 2016 (2015-12-31 to 2016-03-31, filed 2016-05-16); Q4 2015 (2015-09-30 to 2015-12-31, filed 2016-02-16); Q3 2015 (2015-06-30 to 2015-09-30, filed 2015-11-16); Q2 2015 (2015-03-31 to 2015-06-30, filed 2015-08-14); Q1 2015 (2014-12-31 to 2015-03-31, filed 2015-05-15); Q4 2014 (2014-09-30 to 2014-12-31, filed 2015-02-17); Q3 2014 (2014-06-30 to 2014-09-30, filed 2014-11-14); Q2 2014 (2014-03-31 to 2014-06-30, filed 2014-08-14); Q1 2014 (2013-12-31 to 2014-03-31, filed 2014-05-15); Q4 2013 (2013-09-30 to 2013-12-31, filed 2014-02-28); Q3 2013 (2013-06-30 to 2013-09-30, filed 2013-11-14). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2010-12-31.
| Quarter | Stock | Country of operation | Class | Shares before | Shares after | Share change | Value before | Value after | Value change | Filed |
|---|
| Q3 2016 | HRTX
HERON THERAPEUTICS INC | United States | COM | 1,250,104 | 2,850,000 | +1,599,896 | $22,564,000 | $49,105,000 | +$26,541,000 | 2016-11-14 |
|---|
| Q3 2016 | DVAX
DYNAVAX TECHNOLOGIES CORP | United States | COM NEW | 547,810 | 1,347,810 | +800,000 | $7,987,000 | $14,139,000 | +$6,152,000 | 2016-11-14 |
|---|
| Q3 2016 | PCRX
PACIRA PHARMACEUTICALS INC | United States | COM | 93,380 | 150,680 | +57,300 | $3,150,000 | $5,156,000 | +$2,006,000 | 2016-11-14 |
|---|
| Q2 2016 | ANGO
ANGIODYNAMICS INC | United States | COM | 2,498,527 | 3,607,282 | +1,108,755 | $30,707,000 | $51,837,000 | +$21,130,000 | 2016-08-15 |
|---|
| Q2 2016 | ADMA
ADMA BIOLOGICS INC | United States | COM | 964,193 | 1,113,293 | +149,100 | $7,800,000 | $6,624,000 | -$1,176,000 | 2016-08-15 |
|---|
| Q1 2016 | CPRX
CATALYST PHARMACEUTICALS INC | United States | COM | 4,183,177 | 8,200,000 | +4,016,823 | $10,249,000 | $9,594,000 | -$655,000 | 2016-05-16 |
|---|
| Q4 2015 | HRTX
HERON THERAPEUTICS INC | United States | COM | 1,862,001 | 2,232,001 | +370,000 | $45,433,000 | $59,594,000 | +$14,161,000 | 2016-02-16 |
|---|
| Q4 2015 | ATRC
ATRICURE INC | United States | COM | 403,519 | 803,519 | +400,000 | $8,841,000 | $18,031,000 | +$9,190,000 | 2016-02-16 |
|---|
| Q4 2015 | ANGO
ANGIODYNAMICS INC | United States | COM | 2,398,527 | 2,498,527 | +100,000 | $31,637,000 | $30,332,000 | -$1,305,000 | 2016-02-16 |
|---|
| Q3 2015 | DVAX
DYNAVAX TECHNOLOGIES CORP | United States | COM NEW | 766,010 | 789,710 | +23,700 | $17,944,000 | $19,379,000 | +$1,435,000 | 2015-11-16 |
|---|
| Q2 2015 | FATE
FATE THERAPEUTICS INC | United States | COM | 70,428 | 1,300,000 | +1,229,572 | $344,000 | $8,411,000 | +$8,067,000 | 2015-08-14 |
|---|
| Q2 2015 | OSUR
ORASURE TECHNOLOGIES INC | United States | COM | 50,000 | 685,528 | +635,528 | $327,000 | $3,695,000 | +$3,368,000 | 2015-08-14 |
|---|
| Q2 2015 | CPRX
CATALYST PHARMACEUTICALS INC | United States | COM | 4,083,177 | 4,183,177 | +100,000 | $17,680,000 | $17,277,000 | -$403,000 | 2015-08-14 |
|---|
| Q2 2015 | ARAY
ACCURAY INC | United States | COM | 700,000 | 1,000,000 | +300,000 | $6,510,000 | $6,740,000 | +$230,000 | 2015-08-14 |
|---|
| Q1 2015 | CPRX
CATALYST PHARM PARTNERS INC | United States | COM | 2,400,000 | 4,083,177 | +1,683,177 | $7,128,000 | $17,680,000 | +$10,552,000 | 2015-05-15 |
|---|
| Q1 2015 | ADMA
ADMA BIOLOGICS INC | United States | COM | 389,193 | 964,193 | +575,000 | $4,347,000 | $9,449,000 | +$5,102,000 | 2015-05-15 |
|---|
| Q4 2014 | CNMD
CONMED CORP | United States | COM | 150,000 | 250,000 | +100,000 | $5,526,000 | $11,240,000 | +$5,714,000 | 2015-02-17 |
|---|
| Q4 2014 | CPRX
CATALYST PHARM PARTNERS INC | United States | COM | 1,400,000 | 2,400,000 | +1,000,000 | $4,648,000 | $7,128,000 | +$2,480,000 | 2015-02-17 |
|---|
| Q4 2014 | AMPH
AMPHASTAR PHARMACEUTICALS IN | United States | COM | 1,977,854 | 2,127,854 | +150,000 | $23,042,000 | $24,704,000 | +$1,662,000 | 2015-02-17 |
|---|
| Q4 2014 | ARAY
ACCURAY INC | United States | COM | 500,000 | 700,000 | +200,000 | $3,630,000 | $5,285,000 | +$1,655,000 | 2015-02-17 |
|---|
| Q3 2014 | ANGO
ANGIODYNAMICS INC | United States | COM | 2,970,510 | 2,975,227 | +4,717 | $48,508,000 | $40,820,000 | -$7,688,000 | 2014-11-14 |
|---|
| Q2 2014 | ANGO
ANGIODYNAMICS INC | United States | COM | 2,592,649 | 2,970,510 | +377,861 | $40,834,000 | $48,508,000 | +$7,674,000 | 2014-08-14 |
|---|
| Q2 2014 | ATRC
ATRICURE INC | United States | COM | 712,495 | 985,193 | +272,698 | $13,402,000 | $18,108,000 | +$4,706,000 | 2014-08-14 |
|---|
| Q2 2014 | HRTX
HERON THERAPEUTICS INC | United States | COM | 2,233,173 | 2,808,173 | +575,000 | $31,063,000 | $34,597,000 | +$3,534,000 | 2014-08-14 |
|---|
| Q2 2014 | EBS
EMERGENT BIOSOLUTIONS INC | United States | COM | 1,805,352 | 2,080,519 | +275,167 | $45,621,000 | $46,728,000 | +$1,107,000 | 2014-08-14 |
|---|
| Q1 2014 | EBS
EMERGENT BIOSOLUTIONS INC | United States | COM | 1,074,048 | 1,805,352 | +731,304 | $24,692,000 | $45,621,000 | +$20,929,000 | 2014-05-15 |
|---|
| Q1 2014 | ATRC
ATRICURE INC | United States | COM | 437,495 | 712,495 | +275,000 | $8,172,000 | $13,402,000 | +$5,230,000 | 2014-05-15 |
|---|
| Q1 2014 | MOH
MOLINA HEALTHCARE INC | United States | COM | 229,300 | 275,000 | +45,700 | $7,968,000 | $10,329,000 | +$2,361,000 | 2014-05-15 |
|---|
| Q1 2014 | ANGO
ANGIODYNAMICS INC | United States | COM | 2,497,049 | 2,592,649 | +95,600 | $42,849,000 | $40,834,000 | -$2,015,000 | 2014-05-15 |
|---|
| Q1 2014 | INFIQ
INFINITY PHARMACEUTICALS INC | United States | COM | 996,000 | 1,326,000 | +330,000 | $13,755,000 | $15,766,000 | +$2,011,000 | 2014-05-15 |
|---|
| Q4 2013 | INFIQ
INFINITY PHARMACEUTICALS INC | United States | COM | 290,000 | 996,000 | +706,000 | $5,055,000 | $13,755,000 | +$8,700,000 | 2014-02-28 |
|---|
| Q3 2013 | ANGO
ANGIODYNAMICS INC | United States | COM | 2,726,651 | 2,826,651 | +100,000 | $30,757,000 | $37,312,000 | +$6,555,000 | 2013-11-14 |
|---|
| Q3 2013 | INFIQ
INFINITY PHARMACEUTICALS INC | United States | COM | 117,172 | 290,000 | +172,828 | $1,897,000 | $5,055,000 | +$3,158,000 | 2013-11-14 |
|---|
Similar Firms
| Firm Name | Country | 13F Value | Holdings |
|---|
| Not available yet |